



GLOBAL JOURNAL OF HUMAN-SOCIAL SCIENCE: I
SURGERIES AND CARDIOVASCULAR SYSTEM
Volume 14 Issue 3 Version 1.0 Year 2014
Type: Double Blind Peer Reviewed International Research Journal
Publisher: Global Journals Inc. (USA)
Online ISSN: 2249-4618 & Print ISSN: 0975-5888

The Frequency of Incidental Thyroid Carcinoma in Patients with Graves' Disease

By Aykut Soyder, Mustafa Ünübol, Serdar Özbaş & Savaş Koçak
Adnan Menderes University Medical Faculty, Turkey

Abstract- Background: The presence of hypoactive nodules in patients with Graves' disease (GD) is an important factor in deciding on surgical treatment. Literatures are inconclusive about the increase in the risk of malignancy in cases of hypoactive nodules accompanying GD. The incidence of incidental malignancy in patients that underwent surgical treatment for GD were evaluated.

Materials and Methods: This study included 108 patients that underwent thyroidectomy due to GD. Hypoactive nodules and diffuse hyperplasia were observed in 59 (54.6%) and 49 (45.4%) of the patients, respectively, during preoperative evaluation. In all 108 patients total thyroidectomy (TT) was the preferred surgical method.

Results: Malignant histopathology was noted in 11 (10.2%) of the 108 patients. The thyroid nodules preoperatively observed in 59 patients were determined to be benign according to fine needle aspiration biopsy (FNAB), which also showed that 7 (11.9%) patients had incidental malignancy.

Keywords: *grave's disease, thyroid nodule, incidental thyroid cancer, surgical treatment.*

GJMR-I Classification: *NLMC Code: QZ 365, WP 460*



Strictly as per the compliance and regulations of:



The Frequency of Incidental Thyroid Carcinoma in Patients with Graves' Disease

The Incidence and Characteristics of Incidental Malignancy in Patients that Underwent Surgical Treatment of Graves' Disease

Aykut Soyder ^α, Mustafa Ünübol ^ο, Serdar Özbaş ^ρ & Savaş Koçak ^ω

Abstract- Background: The presence of hypoactive nodules in patients with Graves' disease (GD) is an important factor in deciding on surgical treatment. Literatures are inconclusive about the increase in the risk of malignancy in cases of hypoactive nodules accompanying GD. The incidence of incidental malignancy in patients that underwent surgical treatment for GD were evaluated.

Materials and Methods: This study included 108 patients that underwent thyroidectomy due to GD. Hypoactive nodules and diffuse hyperplasia were observed in 59 (54.6%) and 49 (45.4%) of the patients, respectively, during preoperative evaluation. In all 108 patients total thyroidectomy (TT) was the preferred surgical method.

Results: Malignant histopathology was noted in 11 (10.2%) of the 108 patients. The thyroid nodules preoperatively observed in 59 patients were determined to be benign according to fine needle aspiration biopsy (FNAB), which also showed that 7 (11.9%) patients had incidental malignancy. Among the 49 patients with diffuse thyroid hyperplasia, but no nodule, 4 (8.2%) were incidentally malignant. Follicular and papillary carcinomas were observed in 1 (9.1%) patient and 10 (90.9%) patients, respectively. Tumor size was ≤ 1 cm in 7 (70%) of the patients with papillary carcinoma. Hyperthyroidism and recurrence were not observed in any of the patients with thyroid carcinoma during a mean follow-up of 27.3 months.

Conclusions: The frequency of incidental thyroid cancer in patients with GD is unignorable high as the present study. The absence of nodules does not rule out the possibility of cancer. TT should be the preferred surgical treatment of GD.

Keywords: grave's disease, thyroid nodule, incidental thyroid cancer, surgical treatment.

I. INTRODUCTION

Graves disease (GD) was first described by Dr. Caleb Hillier Parry and Dr. Robert James Graves' in 1825, followed by Dr. Carl A. Von Basedow in 1840 [1]. Antithyroid drugs and radioactive iodine (RAI) are the classical treatment options; near-total or TT are standard when surgery is preferred [2, 3]. After Shapiro

Author α: Adnan Menderes University Medical Faculty, Department of General Surgery, Aydın, Turkey. e-mail: asoyder@yahoo.com

Author ο: Adnan Menderes University Medical Faculty, Division of Endocrinology, Aydın, Turkey.

Author ρ: Ankara Güven Hospital, Department of Endocrine and Breast Surgery, Ankara, Turkey.

Author ω: Adnan Menderes University Medical Faculty, Department of General Surgery, 09100 Aydın, Turkey.

et al. observed thyroid cancer in 9% of patients with GD, a large number of studies on the relationship between GD and thyroid cancer were conducted [4]. The rate of incidental cancer in patients with GD that underwent thyroidectomy was reported to be 0%-16.6%, and the cancer was clinically more aggressive [5-8]. The variation in the frequency of incidental thyroid cancer and its aggressive clinical course led to questions about the treatment options for patients with GD.

Thyroid nodules are frequently present in patients with GD, occurring in 22%-45% of patients [9-12]. The incidence of malignancy ranges from 0.4% to 9.8% in patients with thyroid nodules; thus, the treatment of nodules in patients with GD remains a controversial issue due to an increased risk of cancer [13-19]. TT prevents recurrence, significantly contributes to the improvement of exophthalmia in GD, and eliminates the malignancy, as observed in the present study (10.2%). These benefits have solidified the role of TT in the treatment of patients with GD [20]. The aim of the present study was to determine the rate of histopathologically observed incidental malignancy in patients that underwent surgical treatment for GD with hypoactive nodule.

The study was reviewed by the appropriate medical ethics committee and was performed in accordance with the medical ethics standards laid down in an appropriate version of the 1964 Declaration of Helsinki. The study was approved by The Institute's Protocol Review Board.

II. MATERIAL AND METHODS

Data obtained from 1627 patients that underwent surgery due to benign pathologies of the thyroid gland at 2 different hospitals between 2003 and 2012 were retrospectively evaluated. This clinic-pathological study included 108 (6.6%) of these patients that had GD and underwent TT. Clinical and laboratory findings and ultrasonography (USG) and scintigraphy data were recorded. None of the 108 patients received RAI therapy or radiotherapy to the neck prior to surgery.

GD was diagnosed based on history, signs of hyperthyroidism, elevated free thyroid hormones (fT3 and fT4), low thyroid-stimulating hormone (TSH) and

anti-TSH receptor antibody (TRAb) levels, and scintigraphic data. Surgical indications were as follows: recurrent disease following antithyroid drug treatment (n = 67 [62%]); signs of compression due to a large goiter (n = 14 [12.9%]); ophthalmopathy (n = 9 [8.3%]); and patient preference (n = 18 [16.7%]). Among the 108 patients, 59 (54.6%) had hypoactive nodules and 49 (45.4%) had diffuse hyperplasia. Fine needle aspiration biopsy (FNAB) results were benign in the patients with dominant nodules. Tumors <10 mm were considered as microcarcinoma.

Statistical analysis: All analyses were performed using the chi-square test and SPSS v.17.0 for Windows. The level of statistical significance was set at P < 0.05. Age, tumor size, and follow-up period are given as mean ± SD (range) values.

III. RESULTS

The mean ± standard deviation (SD) for GD (with or without nodule) and euthyroid patients' ages was found to be 47,1±12,7 years (16–78 years) / 37,5±12,5 years (16-76 years) and the female/male (F:M) ratio was 79/29 and 462/131 (p>0.05) Table-1. Among the 108 patients with GD TT was performed in 67 (62%) cases due to recurrence following antithyroid drug treatment, 14 (12.9%) cases that had signs of compression due to a large goiter, 9 (8.3%) cases with ophthalmopathy, and 18 (16.7%) cases due to patient preference. In 11 of the 108 patients (10.2%) incidental thyroid carcinoma was observed via histopathological examination, 7 of which were among the 59 patients with nodules (11.9%) and 4 of which were among the 49 patients (8.2%) with diffuse hyperplasia, but no nodule.

Table 1 : Age and sex characteristics of Graves' disease and euthyroid patients who had undergone thyroidectomy

Characteristics	Graves disease patients (n:108)	Euthyroid patients (n:593)	P
Age in years (range)	47,14 ± 12.7	37.5 ± 12.5	0.332
Female: Male (F:M) ratio	79/29	462/131	0.573

As shown in Table-2, mean age of the 4 patients with GD was 41.2 ± 6.5years (37-51 years), the F: M ratio was 4:0, and ophthalmopathy was observed in 2 cases. Mean size of incidental thyroid carcinoma based on histopathological examination in the 4 patients with GD was 9.5 ± 4.7 mm (5-15 mm) (2 were ≤10 mm and the other 2 were 11-20 mm). Histopathological diagnosis in all cases was papillary carcinoma (2 were microcarcinomas). One patient had a multifocal tumor and 2 patients were treated with RAI ablation. Recurrence and mortality did not occur during 30 ± 19.2 months (9-55 months) of follow-up.

Among the 7 patients with nodular GD that also had incidental thyroid carcinoma mean age was 35.1 ± 10.3 years (23-54 years), the F:M ratio was 6:1, ophthalmopathy was observed in 3 cases, mean tumor size was 11.5 ± 6.7 mm (5-25 mm) (5 were ≤10 mm, 1 was 11-20 mm, and 1 was ≥21 mm), histopathological

diagnosis was papillary carcinoma in 6 cases (5 had microcarcinoma), and follicular carcinoma was diagnosed in 1 case (the only male patient in the study group). Histopathological characteristics of the tumors were as follows: capsular and vascular invasion (n = 1); capsular invasion only (n = 1); multifocal tumor with capsular and vascular invasion (n = 1); multifocal tumor with capsular invasion (n = 1); multifocal tumor without capsular or vascular invasion (n = 1). In all, 5 patients were treated with RAI ablation therapy. Recurrence and mortality were not observed during 25.7 ± 10.7 months (12-41 months) of follow-up (Table-2). There wasn't a significant difference in tumor size or mean age between the patients with and without nodules (P > 0.05). The clinical and histopathological characteristics of the 11 patients with incidental thyroid carcinoma are shown in Table-3.

Table 2 : Clinical and histopathological characteristics of the patients with incidental malignancy GD and GD with nodules

Characteristics	GD (n = 4)	GD with Nodules (n = 7)	P
Age in years (range)	41.2 ± 6.5 (37-51)	35.1 ± 10.3 (23-54)	1.000
Female: Male (F:M) ratio	4/0	6/1	
Ophthalmopathy (n)	2	3	
Tumor size [mean (range)]	9.5 ± 4.7 (5-15)	11.5 ± 6.7 (5-25)	1.000
<ul style="list-style-type: none"> • ≤10 mm • 11-20 mm • ≥21 mm 	<ul style="list-style-type: none"> 2 2 - 	<ul style="list-style-type: none"> 5 1 1 	
Pathological results			
<ul style="list-style-type: none"> • Rate of incidental malignancy 	8.2% 4 were papillary carcinoma	11.9% 6 were papillary carcinoma	

	(2 microcarcinoma)	(5 microcarcinoma) 1 follicular carcinoma	
• Rate of microcarcinoma	50%	83.3%	
• Multifocal tumor	1	3	
• Capsular invasion	0	4	
• Vascular invasion	0	2	
RAI ablation therapy	2 cases	5 cases	
Follow-up period in months (range)	30 ± 19.2 (9-55)	25.7 ± 10.7 (12-41)	
Recurrence	-	-	
Mortality	-	-	

RAI: Radioactive iodine.

Table 3: Clinical and histopathological characteristics of the patients with GD and thyroid carcinoma

Case	Age (years)	Gender (M, F)	Clinical Diagnosis	Tumor Size (mm)	Pathological Diagnosis	Multifocality	Capsular Invasion	Vascular Invasion	Surgery	Follow-Up Period (months)
1	26.00	F	G + N	9	PC	-	+	+	BTT	23.00
2	37.00	F	G	15	PC	+	-	-	BTT	24.00
3	39.00	F	G	11	PC	-	-	-	BTT	55.00
4	23.00	F	G + N	5	PC	-	+	-	BTT	41.00
5	37.00	F	G + N	6	PC	+	+	+	BTT	26.00
6	33.00	F	G + N	25	PC	-	-	-	BTT	27.00
7	51.00	F	G	5	PC	-	-	-	BTT	32.00
8	38.00	F	G	6	PC	-	-	-	BTT	9.00
9	41.00	M	G + N	20	FC	-	-	-	BTT	12.00
10	54.00	F	G + N	5	PC	+	+	-	BTT	14.00
11	32.00	F	G + N	5	PC	+	-	-	BTT	37.00

F: Female; M: male; G: GD; N: nodule; PC: papillary carcinoma; FC: follicular carcinoma; -: negative result; +: positive result; BTT: bilateral total thyroidectomy.

IV. DISCUSSION

Thyroid nodules are very common in the general population. The incidence of palpable nodules in regions in which iodine deficiency is endemic is 15% and as high as 50% when thyroid USG is used [13, 21]. The incidence of thyroid nodules in autopsy series varies between 40% and 50% [22]. In the present study 59 (54,6%) of 108 patients that underwent surgery due to GD had solid nodules, which is higher than previously reported and might have been due to the fact that in addition to physical examination imaging techniques were used to detect nodules [5, 7, 9, 10].

The incidence of thyroid carcinoma in patients with GD was 10.2% in the present study, versus previously reported rates as high as 16.6% [5-7]. As the number of histological sections applied to a specimen increases so does the probability of a finding of incidental malignancy in patients with GD with or without nodules.

Papillary thyroid carcinoma is the most common pathological subtype of thyroid cancer, with an incidence of 85% [23, 24]. According to World Health Organization (WHO) classification of thyroid cancers, papillary carcinomas ≤10 mm are defined as papillary

microcarcinoma [24]. In the present study 7 (70%) of 10 patients with incidental papillary thyroid carcinoma had microcarcinoma, which is lower than previously reported rates (75%-100%) of papillary microcarcinoma in GD and in the long-term follow-up of these patients mortality was not observed and the recurrence rates were 3.4%-7.7% in 2 studies, whereas in the present study recurrence and mortality did not occur during follow-up of 11 patients [25- 27].

The optimal treatment of patients with nodular GD remains controversial. According to the recent studies, the risk of malignancy is higher in patients with nodular GD and, as such, thyroidectomy is recommended in the early phase of the disease which also facilitates early diagnosis of incidental thyroid carcinoma in endemic regions [28]. In the present study the rate of incidental thyroid malignancy rate was higher in the patients with nodules than in those without nodules (11.9% and 8.2%, respectively). In addition, absence of nodules in GD does not eliminate the risk of malignancy.

Incidentally detected thyroid malignancies in patients with GD are often microcarcinomas; in the present study the papillary microcarcinoma rate was

70%. Most cases of thyroid malignancies in patients with GD were characterized by an insidious clinical course and were detected incidentally; some patients had poor prognosis, developed distant metastases, and died due to disease [29, 30]. The advantages of TT in GD are treatment of hyperthyroidism, prevention of relapse, treatment of compression-induced symptoms, contribution to pregnancy planning, and especially treatment of exophthalmia. In the present study TT was found to be advantageous for preventing malignancy at a considerable rate of 10.2% and facilitating early diagnosis as well. These advantages have solidified the role of bilateral TT in the treatment of GD.

REFERENCES RÉFÉRENCES REFERENCIAS

1. Feliciano DV. Everything you wanted to know about GD. *Am J Surg* 1992;164(5):404-11.
2. Palit TK, Miller CC 3rd, Miltenburg DM. The efficacy of thyroidectomy for GD: a meta-analysis. *J Surg Res* 2000;90(2):161-5.
3. Barakate MS, Agarwal G, Reeve TS, Barraclough B, Robinson B, Delbridge LW. Total thyroidectomy is now the preferred option for the surgical management of GD. *Aust N Z J Surg* 2002;72(5):321-4.
4. Shapiro SJ, Friedman NB, Perzik SL, Catz B. Incidence of thyroid carcinoma in GD. *Cancer* 1970;26(6):1261-70.
5. Dobyns BM, Sheline GE, Workman JB, Tompkins EA, McConahey WM, Becker DV. Malignant and benign neoplasms of the thyroid in patients treated for hyperthyroidism: a report of the cooperative thyrotoxicosis therapy follow-up study. *J Clin Endocrinol Metab* 1974 Jun;38(6):976-98.
6. Angusti T, Codegone A, Pellerito R, Favero A. Thyroid cancer prevalence after radioiodine treatment of hyperthyroidism. *J Nucl Med* 2000 Jun;41(6):1006-9.
7. Pacini F, Elisei R, Di Coscio GC, Anelli S, Macchia E, Concetti R, et al. Thyroid carcinoma in thyrotoxic patients treated by surgery. *J Endocrinol Invest* 1988 Feb;11(2):107-12.
8. Ozaki O, Ito K, Kobayashi K, Toshima K, Iwasaki H, Yashiro T. Thyroid carcinoma in GD. *World J Surg* 1990;14(3):437-41.
9. Belfiore A, Russo D, Vigneri R, Filetti S. GD, thyroid nodules and thyroid carcinoma. *Clin Endocrinol* 2001;55(6):711-8.
10. Carnell NE, Valente WA. Thyroid nodules in GD: classification, characterization, and response to treatment. *Thyroid* 1988;8(7):571-6.
11. Kraimps JL, Bouin-Pineau MH, Mathonnet M, De Calan L, Ronceray J, Visset J et al. Multicentre study of thyroid nodules in patients with GD. *Br J Surg* 2000;87(8):1111-3.
12. Mishra A, Mishra S. Thyroid nodules in GD: implications in an endemically iodine deficient area. *J Postgrad Med* 2001;47(4):244-7.
13. Silver RJ, Parangi S. Management of thyroid incidentalomas. *Surg Clin North Am* 2004;84(3):907-19.
14. Cantalamessa L, Baldini M, Orsatti A, Meroni L, Amodei V, Castagnone D. Thyroid nodules in GD and the risk of thyroid carcinoma. *Arch Intern Med* 1999;159(15):1705-8.
15. Chao TC, Lin JD, Jeng LB, Chen MF. Thyroid carcinoma with concurrent hyperthyroidism. *Arch Surg* 1999;134(2):130-4.
16. Gerenova J, Buysschaert M, Burbure CY, Daumerie C. Prevalence of thyroid carcinoma in GD: a retrospective study a cohort of 103 patients treated surgically. *Eur J Intern Med* 2003;14(5):321-5.
17. Mazzeferri EL. Thyroid carcinoma and Graves's disease. *J Clin Endocrinol Metab* 1990;70(4):826-9.
18. Okamoto T, Iihara M, Obara T. Management of hyperthyroidism due to Graves' and nodular diseases. *World J Surg* 2000;24(8):957-61.
19. Terzioğlu T, Tezelman S, Onaran Y, Tanakol R. Concurrent hyperthyroidism and thyroid carcinoma. *Br J Surg* 1993;80(10):1301-2.
20. Koyuncu A, Aydın C, Topçu Ö, Gökçe ON, Elagöz Ş, Dökmetaş HS. Could total thyroidectomy become the Standard treatment for GD? *Surg Today* 2011;40(1):22-5.
21. Brander A, Viikinkoski P, Nickels J, Kivisaari L. Thyroid gland: US screening in a random adult population. *Radiology* 1991;181:683-7.
22. Sampson RJ, Woolner LB, Bahn RC, Kurland LT. Occult thyroid carcinoma in Olmsted County, Minnesota: prevalence at autopsy compared with that in Hiroshima and Nagasaki, Japan. *Carcinoma* 1974;34:2072-6.
23. Harach HR, Franssila KO, Wasenius V. Occult papillary carcinoma of the thyroid, a 'normal' findings in Finland. A systematic autopsy study. *Cancer* 1986;58:715-9.
24. Hedinger C, Williams ED, Sobin LH. Histological typing of thyroid tumours. In: WHO International Histological Classification of Tumours. 2nd ed. Berlin: Springer; 1988:9-11.
25. Bramley MD, Harrison BJ. Papillary microcarcinoma of the thyroid gland. *Br J Surg* 1996;83:1674-83.
26. Kasuga Y, Sugeno A, Kobayashi S, et al. Clinical evaluation of the response to surgical treatment of Graves' disease. *Surg Gynecol Obstet* 1990;170:327.
27. Pellegriti G, Belfiore A, Giuffrida D, et al. Outcome of differentiated thyroid cancer in Graves' patients. *J Clin Endocrinol Metab* 1998;83:2805-9.
28. Sakorafas GH, Giotakis J, Stafyla V. Papillary thyroid microcarcinoma: a surgical perspective. *Cancer Treat Rev* 2005;31:423-38.

29. Farbota LM, Calandra DB, Lawrence AM, et al. Thyroid carcinoma in GD. Surgery 1985;98:1148 – 52.
30. Behar R, Arganini M, Wu TC, et al. GD and thyroid cancer. Surgery 1986;100:1121–7.



This page is intentionally left blank